Related Experiment Video
Updated: Jul 14, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
RAP80/UIMC1 as cancer-associated antigen: alternative splice variants and their immunogenicity
Yuriy V Shebzukhov1, Ekaterina P Koroleva, Svetlana V Khlgatian
1Department of Molecular Immunology, Belozersky Institute of Physico-Chemical Biology, Moscow State University, Vorobjovy Gory, Moscow 119899, Russia.
Abstract:
We have identified RAP80/UIMC1, the protein highly expressed in testis, as a new cancer-associated antigen. Sera from 5% to 10% of patients with different types of cancer contain specific antibodies to RAP80/UIMC1. In order to investigate the possible reasons for RAP80/UIMC1 immunogenicity, we characterized its numerous splice isoforms and mapped immunogenic regions of the protein. The majority of RAP80/UIMC1 transcripts was detected both in normal tissues and in colon tumors. There are several RAP80/UIMC1 isoforms that are predominantly expressed in testis, however we did not observe elevated expression of these transcripts in tumors from seropositive patients. We mapped the major immunogenic region of RAP80/UIMC1 to the central part of the protein encoded by exon 9 which is present in a number of ubiquitous splice forms. Thus, based on our data, autoreactivity to RAP80/UIMC1 is related to reasons other than overexpression or tumor-specific splicing.
Insights
Researchers identified RAP80/UIMC1 as a novel cancer antigen. Autoreactivity to this protein in cancer patients stems from common splice forms, not tumor-specific expression.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- RAP80/UIMC1 is a protein highly expressed in the testis.
- Antibodies against RAP80/UIMC1 are found in 5-10% of cancer patients.
- The immunogenicity of RAP80/UIMC1 in cancer warrants investigation.
Purpose of the Study:
- To investigate the reasons behind RAP80/UIMC1 immunogenicity in cancer patients.
- To characterize RAP80/UIMC1 splice isoforms.
- To map the immunogenic regions of RAP80/UIMC1.
Main Methods:
- Analysis of RAP80/UIMC1 splice isoforms.
- Mapping of immunogenic protein regions.
- Transcript expression analysis in normal and tumor tissues.
Main Results:
- RAP80/UIMC1 transcripts are widely detected in normal tissues and colon tumors.
- No elevated expression of testis-predominant RAP80/UIMC1 isoforms was observed in tumors from seropositive patients.
- The primary immunogenic region of RAP80/UIMC1 is located in the central part, encoded by exon 9, present in ubiquitous splice forms.
Conclusions:
- Autoreactivity to RAP80/UIMC1 in cancer patients is not due to overexpression or tumor-specific splicing.
- The immunogenicity is linked to common splice variants containing the immunogenic exon 9.
- Further research is needed to elucidate the precise mechanisms driving RAP80/UIMC1 autoimmunity in cancer.
Related Concept Videos
RNA Splicing
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...
